Kiadis Pharma N.V. announced earnings results for the full year ended December 31, 2020. For the full year, the company announced sales was EUR 17.500 million. Operating loss was EUR 34.105 million compared to EUR 73.234 million a year ago. Net loss was EUR 81.940 million compared to EUR 52.635 million a year ago. Basic loss per share from continuing operations was EUR 2.24 compared to EUR 1.92 a year ago.